Gender, brain-derived neurotrophic factor Val66Met, and frequency of methamphetamine use.
|Title||Gender, brain-derived neurotrophic factor Val66Met, and frequency of methamphetamine use.|
|Publication Type||Journal Article|
|Year of Publication||2012|
|Authors||Heinzerling, KG, Shoptaw S|
|Date Published||2012 Apr|
Frequency of pretreatment methamphetamine (MA) use is an important predictor of outcomes of treatment for MA dependence. Preclinical studies suggest females self-administer more MA than males, but few clinical studies have examined potential sex differences in the frequency of MA use. Estrogen increases expression of brain-derived neurotrophic factor (BDNF), which has effects on MA-induced striatal dopamine release and protects against MA-induced neurotoxicity.
|Alternate Journal||Gend Med|